Literature DB >> 19010902

Hypoxia-mediated induction of the polyamine system provides opportunities for tumor growth inhibition by combined targeting of vascular endothelial growth factor and ornithine decarboxylase.

Katrin J Svensson1, Johanna E Welch, Paulina Kucharzewska, Per Bengtson, Maria Bjurberg, Sven Påhlman, Gerdy B Ten Dam, Lo Persson, Mattias Belting.   

Abstract

Hypoxia is a hallmark of solid tumors, which may offer opportunities for targeted therapies of cancer; however, the mechanisms that link hypoxia to malignant transformation and tumor progression are not fully understood. Here, we show that up-regulation of the polyamine system promotes cancer cell survival during hypoxic stress. Hypoxia was found to induce polyamine transport and the key enzyme of polyamine biosynthesis, ornithine decarboxylase (ODC), in a variety of cancer cell lines. Increased ODC protein expression was shown in hypoxic, GLUT-1-expressing regions of tumor spheroids and experimental tumors, as well as in clinical tumor specimens. Hypoxic induction of the polyamine system was dependent on antizyme inhibitor (i.e., a key positive regulator of ODC and polyamine transport), as shown by RNA interference experiments. Interestingly, depletion of the polyamines during hypoxia resulted in increased apoptosis, which indicates an essential role of the polyamines in cancer cell adaptation to hypoxic stress. These results were supported by experiments in an in vivo glioma tumor model, showing significantly enhanced antitumor effects of the antiangiogenic, humanized anti-vascular endothelial growth factor (VEGF) antibody bevacizumab when used in combination with the well-established, irreversible inhibitor of ODC, alpha-difluoromethylornithine. Our results provide important insights into the hypoxic stress response in malignant cells and implicate combined targeting of VEGF and ODC as an alternative strategy to treat cancer disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19010902     DOI: 10.1158/0008-5472.CAN-08-2340

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Untargeted and stable isotope-assisted metabolomic analysis of MDA-MB-231 cells under hypoxia.

Authors:  Jie Yang; Jianhua Cheng; Bo Sun; Haijing Li; Shengming Wu; Fangting Dong; Xianzhong Yan
Journal:  Metabolomics       Date:  2018-02-27       Impact factor: 4.290

2.  OCT2 and MATE1 provide bidirectional agmatine transport.

Authors:  Tate N Winter; William F Elmquist; Carolyn A Fairbanks
Journal:  Mol Pharm       Date:  2010-12-03       Impact factor: 4.939

3.  Knockdown of antizyme inhibitor decreases prostate tumor growth in vivo.

Authors:  Rachelle R Olsen; Ivy Chung; Bruce R Zetter
Journal:  Amino Acids       Date:  2011-09-11       Impact factor: 3.520

Review 4.  Polyamines in cancer: integrating organismal metabolism and antitumour immunity.

Authors:  Cassandra E Holbert; Michael T Cullen; Robert A Casero; Tracy Murray Stewart
Journal:  Nat Rev Cancer       Date:  2022-04-27       Impact factor: 69.800

5.  Arginase 2 Suppresses Renal Carcinoma Progression via Biosynthetic Cofactor Pyridoxal Phosphate Depletion and Increased Polyamine Toxicity.

Authors:  Joshua D Ochocki; Sanika Khare; Markus Hess; Daniel Ackerman; Bo Qiu; Jennie I Daisak; Andrew J Worth; Nan Lin; Pearl Lee; Hong Xie; Bo Li; Bradley Wubbenhorst; Tobi G Maguire; Katherine L Nathanson; James C Alwine; Ian A Blair; Itzhak Nissim; Brian Keith; M Celeste Simon
Journal:  Cell Metab       Date:  2018-05-10       Impact factor: 27.287

6.  eIF5A promotes translation elongation, polysome disassembly and stress granule assembly.

Authors:  Chi Ho Li; Takbum Ohn; Pavel Ivanov; Sarah Tisdale; Paul Anderson
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

Review 7.  Antizyme and antizyme inhibitor, a regulatory tango.

Authors:  Chaim Kahana
Journal:  Cell Mol Life Sci       Date:  2009-04-28       Impact factor: 9.261

8.  ATP13A3 and caveolin-1 as potential biomarkers for difluoromethylornithine-based therapies in pancreatic cancers.

Authors:  Meenu Madan; Arjun Patel; Kristen Skruber; Dirk Geerts; Deborah A Altomare; Otto Phanstiel Iv
Journal:  Am J Cancer Res       Date:  2016-06-01       Impact factor: 6.166

9.  Harnessing the polyamine transport system to treat BRAF inhibitor-resistant melanoma.

Authors:  Eric T Alexander; Olivia El Naggar; Erin Fahey; Kelsey Mariner; Julia Donnelly; Katelyn Wolfgang; Otto Phanstiel; Susan K Gilmour
Journal:  Cancer Biol Ther       Date:  2021-02-18       Impact factor: 4.742

10.  A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.

Authors:  Tracy Murray Stewart; Daniel Von Hoff; Michael Fitzgerald; Laurence J Marton; Carlos H Roberto Becerra; Thomas E Boyd; Paul R Conkling; Lawrence E Garbo; Robert M Jotte; Donald A Richards; David A Smith; Joe J Stephenson; Nicholas J Vogelzang; Hillary H Wu; Robert A Casero
Journal:  Cancer Chemother Pharmacol       Date:  2020-11-19       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.